NeoStem: Safety board recommends continuing heart-drug trial


NeoStem (NBS +2.2%) say that the Data Safety Monitoring Board for the Phase II trial of its AMR-001 drug has recommended continuing the study following a third interim data and safety review.

AMR-001 is being tested for its ability to preserve heart function after a severe heart attack, with the trial comprising 160 patients. (PR)

Comments (2)
  • dcmjboston
    , contributor
    Comment (1) | Send Message
     
    Over 10% drop yesterday, pretty good recovery today, and the only news anyone following this had to say on NBS was a rumor yesterday and the terse statement above?
    17 Sep 2013, 09:52 PM Reply Like
  • holborn
    , contributor
    Comments (40) | Send Message
     
    Probio is a trader he gains money with his rumour
    18 Sep 2013, 01:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs